Host |
Mouse |
Klon |
8G7G3/1 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Normal thyroid or lung. |
Verdünnung |
1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Rat TTF-1 recombinant protein |
Lokalisation |
Nucleus |
TTF-1
|
Zeta Corporation |
8G7G3/1 |
0.1 ml |
Concentrate |
CE/IVD |
Z2069MT |
-
|
Host |
Mouse |
Klon |
SPT24 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Lung Adeno-CA |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Nuclear |
TTF-1 (Thyroid Transcription Factor 1)
|
Biocare Medical |
SPT24 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3126A |
-
|
Host |
Mouse |
Klon |
SPT24 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Lung Adeno-CA |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Nuclear |
TTF-1 (Thyroid Transcription Factor 1)
|
Biocare Medical |
SPT24 |
1 ml |
Concentrate |
CE/IVD |
ACI3126C |
-
|
Host |
Mouse |
Klon |
SPT24 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Lung Adeno-CA |
Verdünnung |
- |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Nuclear |
TTF-1 (Thyroid Transcription Factor 1)
|
Biocare Medical |
SPT24 |
6 ml |
Ready-to-use |
CE/IVD |
API3126AA |
-
|
Host |
Rabbit |
Klon |
ZR176 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Normal thyroid or lung |
Verdünnung |
1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant TTF-1 protein |
Lokalisation |
Nucleus |
TTF-1 (Thyroid Transcription Factor 1)
|
Zeta Corporation |
ZR176 |
1 ml |
Concentrate |
CE/IVD |
Z2370RL |
-
|
Host |
Rabbit |
Klon |
ZR176 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Normal thyroid or lung |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant TTF-1 protein |
Lokalisation |
Nucleus |
TTF-1 (Thyroid Transcription Factor 1)
|
Zeta Corporation |
ZR176 |
7 ml |
Ready-to-use |
CE/IVD |
Z2370RP |
-
|
Host |
Rabbit |
Klon |
ZR176 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Normal thyroid or lung |
Verdünnung |
1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant TTF-1 protein |
Lokalisation |
Nucleus |
TTF-1 (Thyroid Transcription Factor 1)
|
Zeta Corporation |
ZR176 |
0.5 ml |
Concentrate |
CE/IVD |
Z2370RS |
-
|
Host |
Rabbit |
Klon |
ZR176 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Normal thyroid or lung |
Verdünnung |
1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant TTF-1 protein |
Lokalisation |
Nucleus |
TTF-1 (Thyroid Transcription Factor 1)
|
Zeta Corporation |
ZR176 |
0.1 ml |
Concentrate |
CE/IVD |
Z2370RT |
-
|
Host |
Mouse + Rabbit |
Klon |
8G7G3/1+EP42 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Lung adenocarcinoma and lung squamouse cell carcinoma |
Verdünnung |
- |
Isotyp |
Mouse IgG1+Rabbit IgG1 |
Lokalisation |
Nucleus and cytoplasm |
TTF-1 + Cytokeratin 5
|
Biocare Medical |
8G7G3/1+EP42 |
6 ml |
Ready-to-use |
CE/IVD |
PM425DSAA |
-
|
Host |
Mouse |
Klon |
8G7G3/1+D5/16B4 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Lung, Skin |
Verdünnung |
1:50 |
Isotyp |
Mouse |
Lokalisation |
Nuclear, Cytoplasmic |
TTF-1 + Cytokeratin 5/6 Cocktail
|
Zytomed Systems GmbH |
8G7G3/1+D5/16B4 |
1 ml |
Concentrate |
RUO |
CO004K |
-
|
Host |
Mouse |
Klon |
8G7G3/1+D5/16B4 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Lung, Skin |
Verdünnung |
1:50 |
Isotyp |
Mouse |
Lokalisation |
Nuclear, Cytoplasmic |
TTF-1 + Cytokeratin 5/6 Cocktail
|
Zytomed Systems GmbH |
8G7G3/1+D5/16B4 |
0.5 ml |
Concentrate |
RUO |
CO004K-05 |
-
|
Host |
Mouse |
Klon |
8G7G3/1+D5/16B4 |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Lung, Skin |
Verdünnung |
- |
Isotyp |
Mouse |
Lokalisation |
Nuclear, Cytoplasmic |
TTF-1 + Cytokeratin 5/6 Cocktail
|
Zytomed Systems GmbH |
8G7G3/1+D5/16B4 |
6 ml |
Ready-to-use |
RUO |
COG004 |
-
|
Host |
Mouse + Rabbit |
Klon |
8G7G3/1+BC15 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Lung adenocarcinoma |
Verdünnung |
- |
Isotyp |
Mouse IgG1+Rabbit IgG |
Lokalisation |
Nucleus and cytoplasm (granular) |
TTF-1 + Napsin A
|
Biocare Medical |
8G7G3/1+BC15 |
6 ml |
Ready-to-use |
CE/IVD |
API3078DSAA |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P, WB, IP |
Vorbehandlung |
Citrate |
Positivkontrolle |
Skin, Lung |
Verdünnung |
1:200 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide from aa 426-450 of human tubulin alpha. |
Lokalisation |
Cytoplasm |
Tubulin, alpha
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Concentrate |
RUO |
520-4134 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P, WB, IP |
Vorbehandlung |
- |
Positivkontrolle |
Skin, Lung |
Verdünnung |
1:200 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide derived from aa 416-430 of human tubulin beta. |
Lokalisation |
Cytoplasm |
Tubulin, beta
|
Zytomed Systems GmbH |
polyclonal |
0.5 ml |
Concentrate |
RUO |
520-3812 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P, WB, IP |
Vorbehandlung |
- |
Positivkontrolle |
Skin, Lung |
Verdünnung |
1:200 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide derived from aa 416-430 of human tubulin beta. |
Lokalisation |
Cytoplasm |
Tubulin, beta
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Concentrate |
RUO |
520-3814 |
-
|
Host |
Mouse |
Klon |
TU-20 |
Format |
Purified |
Methode |
F, P, WB |
Vorbehandlung |
Citrate pH6 ! (KD 30.6.09) |
Positivkontrolle |
Neuronal Tisuue |
Verdünnung |
1:50 - 1:200 |
Isotyp |
Mouse IgG1 |
Verdünnung |
Synthetic peptide corresponding to an epitope within the C-terminal region of human class III beta tubulin |
Tubulin, beta 3
|
Zytomed Systems GmbH |
TU-20 |
100 µg |
Purified |
RUO |
620-0318 |
-
|
Host |
Mouse |
Klon |
T311 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Melanoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
Tyrosinase
|
Diagnostic Biosystems |
T311 |
1 ml |
Concentrate |
CE/IVD |
MOB290 |
-
|
Host |
Mouse |
Klon |
T311 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Melanoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
Tyrosinase
|
Diagnostic Biosystems |
T311 |
0.1 ml |
Concentrate |
CE/IVD |
MOB290-01 |
-
|
Host |
Mouse |
Klon |
T311 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Melanoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
Tyrosinase
|
Diagnostic Biosystems |
T311 |
0.5 ml |
Concentrate |
CE/IVD |
MOB290-05 |
-
|
Host |
Mouse |
Klon |
T311 |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Melanoma |
Verdünnung |
- |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
Tyrosinase
|
Diagnostic Biosystems |
T311 |
6 ml |
Ready-to-use |
CE/IVD |
PDM150 |
-
|
Host |
Mouse |
Klon |
T311 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Melanoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2a /κ |
Verdünnung |
Recombinant tyrosinase protein |
Lokalisation |
Cytoplasm |
Tyrosinase
|
Zeta Corporation |
T311 |
1.0 ml |
Concentrate |
CE/IVD |
Z2074ML |
-
|
Host |
Mouse |
Klon |
T311 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Melanoma. |
Verdünnung |
- |
Isotyp |
IgG2a /κ |
Verdünnung |
Recombinant tyrosinase protein |
Lokalisation |
Cytoplasm |
Tyrosinase
|
Zeta Corporation |
T311 |
7 ml |
Ready-to-use |
CE/IVD |
Z2074MP |
-
|
Host |
Mouse |
Klon |
T311 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Melanoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2a /κ |
Verdünnung |
Recombinant tyrosinase protein |
Lokalisation |
Cytoplasm |
Tyrosinase
|
Zeta Corporation |
T311 |
0.5 ml |
Concentrate |
CE/IVD |
Z2074MS |
-
|
Host |
Mouse |
Klon |
T311 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Melanoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2a /κ |
Verdünnung |
Recombinant tyrosinase protein |
Lokalisation |
Cytoplasm |
Tyrosinase
|
Zeta Corporation |
T311 |
0.1 ml |
Concentrate |
CE/IVD |
Z2074MT |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Purified |
Methode |
F, P, WB, IF |
Verdünnung |
1:1000 |
Isotyp |
Rabbit IgG |
Verdünnung |
Tyrosine Hydroxylase purified from Pheochromocytoma |
Tyrosine Hydroxylase
|
Zytomed Systems GmbH |
polyclonal |
100 µl |
Purified |
RUO |
620-0336 |
-
|
Host |
Mouse |
Klon |
1B4-UB |
Format |
Purified |
Methode |
F, EL, WB, FL, P |
Verdünnung |
1:500 - 1:1000 (P) |
Isotyp |
Mouse IgG1 |
Verdünnung |
Ubiquitin from bovine erythrocytes conjugated to bovine gamma globulin |
Ubiquitin
|
Zytomed Systems GmbH |
1B4-UB |
100 µg |
Purified |
RUO |
621-0004 |
-
|
Host |
Monospecific Mouse |
Klon |
ZM191 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Brain. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2a /κ |
Verdünnung |
Recombinant human Ubiquitin protein fragment (around aa 1-119) |
Lokalisation |
Cytoplasm and Cell membrane |
Ubiquitin
|
Zeta Corporation |
ZM191 |
1 ml |
Concentrate |
CE/IVD |
Z2504ML |
-
|
Host |
Monospecific Mouse |
Klon |
ZM191 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Brain. |
Verdünnung |
- |
Isotyp |
IgG2a /κ |
Verdünnung |
Recombinant human Ubiquitin protein fragment (around aa 1-119) |
Lokalisation |
Cytoplasm and Cell membrane |
Ubiquitin
|
Zeta Corporation |
ZM191 |
7 ml |
Ready-to-use |
CE/IVD |
Z2504MP |
-
|
Host |
Monospecific Mouse |
Klon |
ZM191 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Brain. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2a /κ |
Verdünnung |
Recombinant human Ubiquitin protein fragment (around aa 1-119) |
Lokalisation |
Cytoplasm and Cell membrane |
Ubiquitin
|
Zeta Corporation |
ZM191 |
0.5 ml |
Concentrate |
CE/IVD |
Z2504MS |
-
|
Host |
Monospecific Mouse |
Klon |
ZM191 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Brain. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2a /κ |
Verdünnung |
Recombinant human Ubiquitin protein fragment (around aa 1-119) |
Lokalisation |
Cytoplasm and Cell membrane |
Ubiquitin
|
Zeta Corporation |
ZM191 |
0.1 ml |
Concentrate |
CE/IVD |
Z2504MT |
-
|
Host |
Mouse+Rabbit |
Klon |
Ks20.8+EP9 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
p53 positive bladder or colon cancer |
Verdünnung |
- |
Isotyp |
Mouse IgG1 and Rabbit IgG |
Lokalisation |
Nuclear (p53) and cytoplasmic (CK20) |
URO-2TM (Cytokeratin 20 + p53)
|
Biocare Medical |
Ks20.8+EP9 |
6 ml |
Ready-to-use |
CE/IVD |
API3001DSAA |
-
|
Host |
Mouse + Rabbit |
Klon |
156-3C11+EP9+Ks20.8 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Some bladder and colon carcinomas |
Verdünnung |
- |
Isotyp |
MouseIgG2a+RabbitIgG+MouseIgG2a |
Lokalisation |
Cytoplasm and nucleus |
URO-3 Triple StainTM (CD44 + Cytokeratin 20 + p53)
|
Biocare Medical |
156-3C11+EP9+Ks20.8 |
6 ml |
Ready-to-use |
CE/IVD |
PM370TSAA |
-
|
Host |
Mouse |
Klon |
ZM204 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Bladder or urothelial carcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b/κ & IgG1/κ |
Verdünnung |
Recombinant fragment (around aa 114-173) of human Uroplakin 1A (UPK1A) protein. Recombinant fragment (around aa 109-229) of human Uroplakin 1B (UPK1B) |
Lokalisation |
Cytoplasm and Cell membrane |
Uroplakin
|
Zeta Corporation |
ZM204 |
1 ml |
Concentrate |
CE/IVD |
Z2522ML |
-
|
Host |
Mouse |
Klon |
ZM204 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Bladder or urothelial carcinoma |
Verdünnung |
- |
Isotyp |
IgG2b/κ & IgG1/κ |
Verdünnung |
Recombinant fragment (around aa 114-173) of human Uroplakin 1A (UPK1A) protein. Recombinant fragment (around aa 109-229) of human Uroplakin 1B (UPK1B) |
Lokalisation |
Cytoplasm and Cell membrane |
Uroplakin
|
Zeta Corporation |
ZM204 |
7 ml |
Ready-to-use |
CE/IVD |
Z2522MP |
-
|
Host |
Mouse |
Klon |
ZM204 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Bladder or urothelial carcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b/κ & IgG1/κ |
Verdünnung |
Recombinant fragment (around aa 114-173) of human Uroplakin 1A (UPK1A) protein. Recombinant fragment (around aa 109-229) of human Uroplakin 1B (UPK1B) |
Lokalisation |
Cytoplasm and Cell membrane |
Uroplakin
|
Zeta Corporation |
ZM204 |
0.5 ml |
Concentrate |
CE/IVD |
Z2522MS |
-
|
Host |
Mouse |
Klon |
ZM204 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Bladder or urothelial carcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b/κ & IgG1/κ |
Verdünnung |
Recombinant fragment (around aa 114-173) of human Uroplakin 1A (UPK1A) protein. Recombinant fragment (around aa 109-229) of human Uroplakin 1B (UPK1B) |
Lokalisation |
Cytoplasm and Cell membrane |
Uroplakin
|
Zeta Corporation |
ZM204 |
0.1 ml |
Concentrate |
CE/IVD |
Z2522MT |
-
|
Host |
Rabbit |
Klon |
DBRRM3.66 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Bladder |
Verdünnung |
1:100-1:200 |
Isotyp |
IgG kappa |
Verdünnung |
Recombinant human Uroplakin 3Bprotein fragment (around aa 100-300) |
Lokalisation |
Membranous |
Uroplakin 3B
|
Diagnostic Biosystems |
DBRRM3.66 |
1 ml |
Concentrate |
Übergangsfrist |
RMAB117R |
-
|
Host |
Rabbit |
Klon |
DBRRM3.66 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Bladder |
Verdünnung |
1:100-1:200 |
Isotyp |
IgG kappa |
Verdünnung |
Recombinant human Uroplakin 3Bprotein fragment (around aa 100-300) |
Lokalisation |
Membranous |
Uroplakin 3B
|
Diagnostic Biosystems |
DBRRM3.66 |
0.1 ml |
Concentrate |
Übergangsfrist |
RMAB117R-01 |
-
|
Host |
Rabbit |
Klon |
DBRRM3.66 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Bladder |
Verdünnung |
1:100-1:200 |
Isotyp |
IgG kappa |
Verdünnung |
Recombinant human Uroplakin 3Bprotein fragment (around aa 100-300) |
Lokalisation |
Membranous |
Uroplakin 3B
|
Diagnostic Biosystems |
DBRRM3.66 |
0.5 ml |
Concentrate |
Übergangsfrist |
RMAB117R-05 |
-
|
Host |
Rabbit |
Klon |
DBRRM3.66 |
Format |
ready-to-use |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Bladder |
Verdünnung |
--- |
Isotyp |
IgG kappa |
Verdünnung |
Recombinant human Uroplakin 3Bprotein fragment (around aa 100-300) |
Lokalisation |
Membranous |
Uroplakin 3B
|
Diagnostic Biosystems |
DBRRM3.66 |
6 ml |
ready-to-use |
Übergangsfrist |
RMPD117R |
-
|
Host |
Mouse |
Klon |
BC21 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Normal bladder or urothelial carcinoma of the bladder |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG1 kappa |
Verdünnung |
Recombinant human Uroplakin II protein |
Lokalisation |
Cytoplasm and cytoplasmic membrane |
Uroplakin II
|
Biocare Medical |
BC21 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3051A |
-
|
Host |
Mouse |
Klon |
BC21 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Normal bladder or urothelial carcinoma of the bladder |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG1 kappa |
Verdünnung |
Recombinant human Uroplakin II protein |
Lokalisation |
Cytoplasm and cytoplasmic membrane |
Uroplakin II
|
Biocare Medical |
BC21 |
1 ml |
Concentrate |
CE/IVD |
ACI3051C |
-
|
Host |
Mouse |
Klon |
BC21 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Normal bladder or urothelial carcinoma of the bladder |
Verdünnung |
- |
Isotyp |
Mouse IgG1 kappa |
Verdünnung |
Recombinant human Uroplakin II protein |
Lokalisation |
Cytoplasm and cytoplasmic membrane |
Uroplakin II
|
Biocare Medical |
BC21 |
6 ml |
Ready-to-use |
CE/IVD |
API3051AA |
-
|
Host |
Mouse |
Klon |
BC21 |
Format |
Ready-to-use |
Methode |
P |
Positivkontrolle |
Normal bladder or urothelial carcinoma of the bladder |
Verdünnung |
- |
Isotyp |
Mouse IgG1 kappa |
Verdünnung |
Recombinant human Uroplakin II protein |
Lokalisation |
Cytoplasmic and membrane |
Uroplakin II
|
Biocare Medical |
BC21 |
6 ml |
Ready-to-use |
CE/IVD |
AVI3051KG |
-
|
Host |
Mouse + Mouse |
Klon |
BC21 + BC17 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Urothelial carcinoma or normal bladder |
Verdünnung |
- |
Isotyp |
Mouse IgG1 + Mouse IgG1 |
Lokalisation |
Cytoplasmic membrane + cytoplasm |
Uroplakin II + Uroplakin III
|
Biocare Medical |
BC21 + BC17 |
6 ml |
Ready-to-use |
CE/IVD |
API3094AA |
-
|
Host |
Mouse |
Klon |
BC17 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Reveal modified Citrate pH 6.0 |
Positivkontrolle |
Bladder cancer |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasmic, membrane |
Uroplakin III
|
Biocare Medical |
BC17 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3023A |
-
|
Host |
Mouse |
Klon |
BC17 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Reveal modified Citrate pH 6.0 |
Positivkontrolle |
Bladder cancer |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasmic, membrane |
Uroplakin III
|
Biocare Medical |
BC17 |
1 ml |
Concentrate |
CE/IVD |
ACI3023C |
-
|
Host |
Mouse |
Klon |
BC17 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Reveal modified Citrate pH 6.0 |
Positivkontrolle |
Bladder cancer |
Verdünnung |
- |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasmic, membrane |
Uroplakin III
|
Biocare Medical |
BC17 |
6 ml |
Ready-to-use |
CE/IVD |
API3023AA |
-
|
Host |
Mouse |
Klon |
AU1 |
Format |
Concentrate |
Methode |
P, WB |
Vorbehandlung |
Fast Enzyme or Citrate |
Positivkontrolle |
Urothial carcinoma |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Urethelial surface membrane |
Uroplakin III
|
Zytomed Systems GmbH |
AU1 |
0.5 ml |
Concentrate |
RUO |
MSK052-05 |
-
|